Ausgewählte Studien

Scand J Rheumatol. 2024 Jan 8:1-6. doi: 10.1080/03009742.2023.2295723. Online ahead of print. ABSTRACT OBJECTIVES: Screening tools are needed to help to identify psoriatic arthritis in patients with psoriasis. The Psoriatic arthritis UnclutteRed screening Evaluation (PURE-4) questionnaire was developed for this purpose and has been shown to perform very well. The aim of this study was to translate and culturally adapt the PURE-4 scale into the Danish language. METHOD: The translational process f

J Dtsch Dermatol Ges. 2024 Feb;22(2):278-281. doi: 10.1111/ddg.15292. Epub 2024 Jan 7. NO ABSTRACT PMID:38185772 | DOI:10.1111/ddg.15292 Den ganzen Artikel lesen

Plaque psoriasis is a chronic, immunemediated skin disease characterized by scaly, erythematous, pruritic plaques. The effects of psoriasis are often …Den ganzen Artikel lesen

Objective: This study aims to evaluate the effect of functional versus resistance exercise training on the functional capacity and quality of life of …Den ganzen Artikel lesen

Full text linksCite Display options Display options Immune-mediated inflammatory diseases (IMIDs) constitute a heterogenous group of chronic and highly …Den ganzen Artikel lesen

Full text linksCite Display options Display options Objectives: To assess the impact of low to moderate biomechanical stress on entheses in patients …Den ganzen Artikel lesen

Background: Chronic inflammatory diseases (immune-mediated inflammatory diseases, IMID) can overlap or occur simultaneously due to clinical …Den ganzen Artikel lesen

Background: Immunosuppression is a known risk factor for the development of cutaneous squamous cell carcinoma (CSCC), especially in solid organ …Den ganzen Artikel lesen

Background: The risk of developing cutaneous T cell lymphoma (CTCL) in patients using psoriasis biologics has not been well characterized. The goals …Den ganzen Artikel lesen

Analysis of Online Communities' Needs Among Psoriasis Patients on Social MediaDen ganzen Artikel lesen

Background: Few studies have used real-world data to investigate the association between biologic therapy survival and age at psoriasis onset or …Den ganzen Artikel lesen

Introduction: Enthesitis is a hallmark of psoriatic disease, but its clinical assessment is problematic in terms of diagnostic sensitivity and …Den ganzen Artikel lesen

Arch Dermatol Res. 2024 Jan 4;316(2):65. doi: 10.1007/s00403-023-02796-y. ABSTRACT Information on the population-based incidence of psoriasis vulgaris was limited. This study was to provide a comprehensive understanding of the age-specific and sex-specific incidence of psoriasis vulgaris in Germany. The data were obtained in the context of a morbidity-based risk adjustment by statutory health insurance companies in Germany, comprising information regarding 65 million population. Psoriasis vulgar

Int J Dermatol. 2024 Jan 2. doi: 10.1111/ijd.16915. Online ahead of print. ABSTRACT BACKGROUND: Biological therapy dose modification is a common practice in the long-term treatment of plaque psoriasis. OBJECTIVE: The objective of the study was to determine prevalence, characteristics of patients, effectiveness, treatment survival of secukinumab dose reduction (SEC-DR) strategy and assess its safety and cost implications. METHODS: A retrospective, observational, multicenter cohort study was condu

Dermatologie (Heidelb). 2024 Jan 2. doi: 10.1007/s00105-023-05288-2. Online ahead of print. NO ABSTRACT PMID:38167779 | DOI:10.1007/s00105-023-05288-2 Den ganzen Artikel lesen

Front Immunol. 2023 Dec 11;14:1256133. doi: 10.3389/fimmu.2023.1256133. eCollection 2023. ABSTRACT Plaque psoriasis is an autoinflammatory and autoimmune skin disease, affecting 1-3% of the population worldwide. Previously, high levels of IL-36 family cytokines were found in psoriatic skin lesions, thereby contributing to keratinocyte hyperproliferation and infiltration of immune cells such as neutrophils. While treatment with anti-IL36 receptor (IL36R) antibodies was recently approved for gener

J Eur Acad Dermatol Venereol. 2023 Dec 28. doi: 10.1111/jdv.19782. Online ahead of print. ABSTRACT BACKGROUND: Prediction of the response to a biological treatment in psoriasis patients would allow efficient treatment allocation. OBJECTIVE: To identify polymorphisms associated with secukinumab response in psoriasis patients in a daily practice setting. METHODS: We studied 180 SNPs in patients with moderate-to-severe plaque psoriasis recruited from 15 Spanish hospitals. Treatment effectiveness wa

J Dtsch Dermatol Ges. 2023 Dec 21. doi: 10.1111/ddg.15269. Online ahead of print. ABSTRACT BACKGROUND AND OBJECTIVES: Few studies are available on the epidemiology of psoriasis and psoriatic arthritis in Germany. The aim of this study was to estimate this prevalence based on different case definitions. METHODS: Statutory health insurance (SHI) data were examined (2017 to 2019). Prevalence was analyzed and validated using three different case definitions: (1) At least one inpatient or outpatient

J Mol Med (Berl). 2023 Dec 21. doi: 10.1007/s00109-023-02406-4. Online ahead of print. ABSTRACT Objective parameters to quantify psoriatic inflammation are needed for interdisciplinary patient care, as well as preclinical experimental models. This study evaluates neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in psoriasis patients and five murine models of psoriasis-like skin disease based on topical imiquimod application and overexpression of IL-17A under different

RMD Open. 2023 Dec 19;9(4):e003538. doi: 10.1136/rmdopen-2023-003538. ABSTRACT BACKGROUND: The influence of sex on treatment outcomes during interleukin-12/23 therapy in patients with psoriatic arthritis (PsA) has not been explored. OBJECTIVE: To conduct exploratory post hoc analyses of sex-stratified data from the MUST trial, an investigator-initiated, multicentre, phase 3b study in which patients with active PsA initiating treatment with open-label ustekinumab were randomised to treatment with

Dermatol Ther (Heidelb). 2023 Dec 19. doi: 10.1007/s13555-023-01086-9. Online ahead of print. ABSTRACT INTRODUCTION: Given the chronic nature of psoriasis (PsO), more studies are needed that directly compare the effectiveness of different biologics over long observation periods. This study compares the effectiveness and durability through 12 months of anti-interleukin (IL)-17A biologics relative to other approved biologics in patients with moderate-to-severe psoriasis in a real-world setting. ME

Dermatologie (Heidelb). 2023 Dec 15. doi: 10.1007/s00105-023-05253-z. Online ahead of print. ABSTRACT Janus kinase inhibitors (JAKi) represent an immunomodulatory targeted therapy in various dermatoses. Throughout the past few years, JAKi have been approved for atopic dermatitis (AD), psoriasis vulgaris (PSO), alopecia areata (AA), and vitiligo. Further indications are currently under investigation. In this article the various systenic and topical JAKi used in dermatology are being presented reg

BMJ Open. 2023 Nov 24;13(11):e074752. doi: 10.1136/bmjopen-2023-074752. ABSTRACT OBJECTIVES: Healthcare ultimately aims to eradicate diseases and restore normality to people's lives. However, until this is achieved for every person, there is a need to support and assist patients with psoriasis using non-pharmacological interventions. These 'adjuvant' approaches have received little attention, whereas dermatologists and researchers strive for better pharmacological therapy. Here, we aimed to perf

Taylor Francis For many patients including those with psoriasis, scientific manuscripts comprising clinical outcomes including psoriasis area severity …Den ganzen Artikel lesen

Background: Co-existing long-term conditions (LTC) in psoriasis and their potential causal associations with the disease are not …Den ganzen Artikel lesen